The primary endpoint miss creates significant regulatory risk, but the statistically significant prespecified subgroup and strong survival data provide a potential path forward. Watch for FDA feedback on the NDA submission and whether the agency accepts the totality-of-data argument. The Q4 2026 NDA timeline is the next binary catalyst.
Price Chart
Executive Summary
Rafael Holdings announced topline results from its pivotal Phase 3 TransportNPC study of Trappsol Cyclo in Niemann-Pick Disease Type C. The primary endpoint did not achieve statistical significance (p=0.19), but a prespecified analysis in ~83% of patients on background miglustat/leucine showed a statistically significant benefit (p=0.046). The company remains on track to submit an NDA in Q4 2026. The mixed data creates regulatory uncertainty despite the positive subgroup signal.
Key Facts
- Phase 3 TransportNPC study (n=94) missed primary endpoint: 4DNPCSS change at Week 96, LS mean difference -0.81 points (95% CI -2.04, 0.41; p=0.19), not statistically significant
- Prespecified analysis in patients on background miglustat/leucine (n=78, ~83% of population) showed statistically significant benefit: LS mean difference -1.11 points (95% CI -2.19, -0.02; p=0.046)
- Separate overall survival analysis in infantile-onset NPC showed 85% mortality risk reduction vs INPDR controls (HR=0.154; 95% CI 0.025-0.950; p=0.044) and 94% reduction vs expanded historical controls (HR=0.057; 95% CI 0.011-0.306; p=0.0008)
- Safety profile consistent with prior studies; serious TEAEs higher in Trappsol group (35.9% vs 16.7% placebo) but treatment-related serious TEAEs similar (3.1% vs 3.3%)
- Company remains on track to submit NDA in Q4 2026 based on previously announced pre-NDA meeting with FDA
Financial Impact
No financial figures provided in filing; NDA submission on track for Q4 2026 with potential for NPC market entry if approved
Risk Factors
- FDA may not accept NDA filing or may require additional trials given primary endpoint miss
- Subgroup analysis (miglustat/leucine background) may not be considered sufficient for approval in the broader NPC population
- Higher serious TEAE rate in Trappsol group (35.9% vs 16.7%) could raise safety concerns during review
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-104876 |
| Document: ea030712501ex99-1.htm | 0001213900-26-104876 |
| Document: 0001213900-26-104876-index-headers.html | 0001213900-26-104876 |
| Document: 0001213900-26-104876-index.html | 0001213900-26-104876 |
| Document: 0001213900-26-104876.txt | 0001213900-26-104876 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 27d ago | 8-K | $1.32 | awaiting T+20 | — | $1.24 (−6.06%) |
Sep 30, 2026 27d ago | Press Release | $1.32 | awaiting T+20 | — | $1.24 (−6.06%) |
Aug 18, 2026 10w ago | Institutional Cluster | $1.86 $2.10 | ▲ +12.90% | ▲ +13.89% | $1.24 (−33.33%) |
Jun 11, 2026 19w ago | 8-K | $2.12 $2.27 | ▲ +7.08% | ▲ +5.18% | $1.24 (−41.51%) |
Jun 10, 2026 19w ago | 8-K | $1.78 $2.27 | ▲ +27.53% | ▲ +23.91% | $1.24 (−30.34%) |
Jun 10, 2026 19w ago | Press Release | $1.78 $2.27 | ▲ +27.53% | ▲ +23.91% | $1.24 (−30.34%) |
Apr 22, 2026 26w ago | 8-K | $1.30 $1.35 | ▲ +3.85% | ▲ +0.68% | $1.24 (−4.62%) |
Mar 16, 2026 32w ago | Press Release | $1.32 $1.22 | ▼ −7.58% | ▼ −11.88% | $1.24 (−6.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers